Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Clofarabine Clear all
Active, not recruiting Phase 3 Interventional

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions
Iomab-B, Conventional Care, HCT
Drug · Procedure
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

NCT00700011
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Clofarabine
Drug
Lead sponsor
Texas Oncology Cancer Center
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

Natural Killer (NK) Cell Transplantation for AML

NCT00187096
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
Drug · Procedure · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

NCT01031368
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

Clofarabine in Chronic Lymphocytic Leukemia

NCT00028418
View directory record Official record
Conditions
Hematologic Neoplasms, Lymphoproliferative Disorders, Leukemia, Leukemia, Lymphocytic, Chronic
Interventions
Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 16, 2026, 11:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

NCT05862324
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
TAC01-CLDN18.2
Biological
Lead sponsor
Triumvira Immunologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 16, 2026, 11:56 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

NCT01983761
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions
Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
Drug
Lead sponsor
Targazyme, Inc.
Industry
Eligibility
1 Year to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

NCT00903760
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Decitabine, Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

NCT01003678
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Clofarabine
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)

NCT00067028
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Clofarabine 40mg/m^2, Idarubicin 10mg/m^2, Ara-C 0.75 g/m^2, Clofarabine 22.5mg/m^2, Ara-C 1 g/m^2, Idarubicin 6 mg/m^2
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 59 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia

NCT01960387
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Clofarabine, Cytarabine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

NCT00042354
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Pediatric
Interventions
clofarabine (IV formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
18
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange County, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 1 Interventional

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias

NCT00852709
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Interventions
Clofarabine, Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)

NCT00373529
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions
clofarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00602225
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
Interventions
clofarabine, cytarabine, filgrastim
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 16, 2026, 11:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

NCT01885689
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
clofarabine, melphalan, allogeneic hematopoietic stem cell transplantation, tacrolimus, sirolimus, Pharmacological Study
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

NCT00943592
View directory record Official record
Conditions
Advanced Hematologic Malignancies, Leukemia, Preleukemia
Interventions
Clofarabine, Melphalan, Campath, Stem Cell Transplant
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease

NCT00863434
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia
Interventions
clofarabine, cytarabine, filgrastim
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

NCT02518750
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Interventions
Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 16, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

NCT00697684
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia, Relapsed/Refractory Non Hodgkin's Lymphoma, Hodgkins Disease, Relapsed Refractory Multiple Myeloma
Interventions
Antithymocyte Globulin, Clofarabine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 16, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

NCT00939653
View directory record Official record
Conditions
Relapsed Acute Myelogenous Leukemia
Interventions
Clofarabine, Etoposide, Cyclophosphamide, Filgrastim, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 16, 2026, 11:56 AM EDT